FLOW CYTOMETRY IN THE DIAGNOSIS AND MONITORING OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA
Over the past 20 years, approaches to the therapy of multiple myeloma have undergone significant changes, and frequency of achieving remission of the disease increased. The new diagnostic methods allowed evaluating the more deep therapy response and predicting the relapse: allele-specific polymerase...
Main Authors: | I. V. Galtseva, Y. O. Davydova, N. M. Kapranov, U. L. Julakyan, L. P. Mendeleeva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2017-06-01
|
Series: | Онкогематология |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/244 |
Similar Items
-
STUDY OF MINIMAL RESIDUAL DISEASE BY MULTICOLOR FLOW CYTOMETRY IN MULTIPLE MYELOMA AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
by: I. V. Galtseva, et al.
Published: (2017-06-01) -
Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium
by: Agnieszka Krzywdzińska, et al.
Published: (2021-10-01) -
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial
by: Alexander Schmitz, et al.
Published: (2022-02-01) -
Minimal Residual Disease in Multiple Myeloma—Current Approaches and Future Clinical Implications
by: Theresia Akhlaghi, et al.
Published: (2022-07-01) -
Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
by: Maura Rosane Valério Ikoma, et al.
Published: (2015-12-01)